AFFILIATIONS
1 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
2 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
3 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
4 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
5 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
6 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
7 Department of Hematology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China, Guangzhou, China
8 Department of Hematology, Maoming People's Hospital, Maoming, China, Guangzhou, China
9 Department of Hematology, The second People’s Hospital of Qin Zhou, QinZhou, China, Guangzhou, China
10 Department of Hematology, Shenzhen Hospital, Southern Medical University, Shenzhen, China, Guangzhou, China
11 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
12 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
13 Department of Hematology, Nanfang Hospital, Southern medical University, Guangzhou, China
ABSTRACT
Background
Measurable residual disease (MRD) positivity post chemotherapy is closely associated with relapse risk in acute myeloid leukemia (AML) . Preclinical studies demonsrtaed venetoclax and sorafenib synergistically kill AML cells in vitro and in vivo. This study aims to evaluate the efficacy and safety of venetoclax combined with sorafenib (VS) for MRD eradication in adult AML.
Methods
This prospective, single-arm, multicentre trial enrolled AML patients aged 18-65 years old, who had achieved a complete remission after conventional chemotherapy, and with positive MRD. Exclusion criteria included acute promyelocytic leukemia, presence of haematological relapse, severe organ function impairment, uncontrolled infection, an absolute neutrophil count less than 1.0×109 cells per L or a platelet count less than 50×109 per L. Patients received venetoclax at 400 mg once daily on days 1-28, in combination with sorafenib at 400mg twice daily on days 1-28 as one cycle. After three cycles, patients with MRD response (MR) continued to received venetoclax and sorafenib for two years and were eligible for a treatment de-escalation.MR was defined as > 1 log10 decrease of MRD level compared to pretreatment. MRD was monitored by either quantitative PCR for mutant NPM1, leukaemia-specific fusion genes (RUNX1–RUNX1T1,CBFb–MYH11) or multiparameter flow cytometry (MFC-MRD). MRD positivity was defined as RUNX1/RUNX1T1/ABL1, CBFB-MYH11/ABL1 ,NPM1/ABL1 ratio, or MFC-MRD of 0.01% or higher in bone marrow sample. The primary endpoint was MR rate after three cycles of VS treatment. The secondary endpoints included MRD negativity rate, cumulative incidence of relapse (CIR) and adverse events (AEs).This trial is registered with ClinicalTrials.gov (NCT07264010) .
Results
Between Dec 1, 2025, and April 30, 2026, a total of 25 MRD positive AML patients in confirmed complete remission were enrolled in this study, including 10 females and 15 males, with a median age of 41 (IQR, 30-50) years. Four patients had NPM1 mutation, 5 patients had RUNX1/RUNX1T1 and 16 patients had CBF/MYH11 fusion gene. The median cycles of intensive chemotherapy before start of VS treatment were 5 (4-6). The median level of MRD before VS treatment was 0.102% (0.060-0.226%). After three cycles of treatment, MR was achieved in 17 of 25 patients (68%), and MRD negativity was achieved in 14 of 25 patients (56%). Among the 17 patients who achieved MR,2 patients suffered from molecular relapse. Among the 8 patients who did not achieve MR, 1 suffered form molecular relapse and 1 hematologic relapse. Rates of grade 3 or higher hematologic toxicities included neutropenia (16.0%), thrombocytopenia (56.0%) and febrile neutropenia (4.0%). The most common grades 1-2 non-hematologic toxicities included diarrhea (20.0%), rash (12.0%) and alanine aminotransferase increase (8%). The most common grades 3 or higher non-hematologic toxicities included rash (8% ). 10 patients (40%) required dose modifications due to adverse events, including 6 dose reductions, 4 dose interruptions. The median tolerated dose of sorafenib was 400 mg/day (IQR 400–800).
Conclusions
Venetoclax plus Sorafenib demonstrated promising efficacy in eradicating MRD in adult AML patients and was generally well tolerated.
DISCLOSURES
Xi Jia: No relevant conflicts of interest to declare.